Dose: 20 ml
Single Dose: 20 (20)
Frequency: As recommended.
Route: IV
Instructions: Intravenous, 20 mL of a solution containing the equivalent of 260 mg of iodine per mL administered slowly over a period of ten minutes, not to be repeated for twenty-four hours.

. The Molecular Weight of Iodipamide Meglumine is 1530.20.

Iodipamide Meglumine is contraindicated in conditions like Hepatic dysfunction,Pregnancy,Renal dysfunction,Hypersensitivity to any component of product.

Iodipamide Meglumine produces potentially life-threatening effects which include Hypersensitivity. which are responsible for the discontinuation of Iodipamide Meglumine therapy.The signs and symptoms that are produced after the acute overdosage of Iodipamide Meglumine include Bradycardia, Hypotension, Anaphylactoid reactions, Cardiac arrest.The symptomatic adverse reactions produced by Iodipamide Meglumine are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Fever, Sweating, Chills, Rashes, Flushing, Nausea and vomiting, dizziness.

Iodipamide Meglumine is primarily indicated in conditions like Cholecystography, Hysterosalpingography.

Iodipamide Meglumine is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementSodium Ipodatehepatic excretion of iodipamide meglumine may be blocked after administration of Sodium Ipodate, increasing the risk of adverse effects.Administration of cholecystographic agents is not recommended within 24 hours before or after iodipamide meglumine. These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Urinanalysis Elevations of SGPT and SGOT Elevation in ALT or ASTIncreased level of Blood urea nitrogen (BUN) concentrationsIncreased in serum creatinin

Drug should not be given to Pregnant Mothers.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Parentral Store Between 20°C-25°C. Protect from Sunlight and Heat.

Diagnostic procedures which involve the use of radiopaque diagnostic agents should be carried out under the direction of personnel with the prerequisite training and with a thorough knowledge of the particular procedure to be performed. The possibility of a reaction should always be considered. Patients at increased risk include those with a history of a previous reaction to a contrast medium, patients with a known sensitivity to iodine, and patients with a known clinical hypersensitivity: bronchial asthma, hay fever, and food allergies.